I’m very pleased that we’ll be able to offer our current and future cell and gene therapy customers even more of what they need from our Milan facility. This is but one of the important steps we are taking to ensure we keep pace with the evolving needs of the market.
This investment is part of our global cell and gene therapy expansion plan in Europe, Asia and the US. All of our innovation and expansion is focused on the needs of our partners and the patients they serve. I look forward to announcing additional expansion plans soon.
The expansion comes less than one year following AGC’s successful acquisition and integration of the former MolMed S.p.A. facilities. The Milan site was the first GMP facility approved in Europe for ex-vivo gene therapy manufacturing and has unique commercial manufacturing experience, with two cell & gene therapy products. AGC Biologics is now one of the very few CDMO’s in the world offering both plasmid production and end-to-end cell and gene therapy services.
Luca Alberici as the New General Manager/Site Head of the Milan, Italy Site
On October 2021 Luca Alberici was named General Manager/Site Head at the Milan, Italy site. He is providing leadership and site management to ensure the continued execution of world-class cell and gene therapy contract development and manufacturing services from the Milan, Italy Site. He will support the continuous growth of the Site while working closely with colleagues in Seattle, Heidelberg and Chiba to ensure the business leverages and integrates AGC Biologics combined global capabilities.